Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 0 · 0%High 2 · 50%

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Overall survival · people with cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Progression‐free survival · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.4 [0.35, 0.46]
738 participants
High

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 3.5 [2.07, 5.92]
738 participants
High

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.57 [0.85, 2.92]
764 participants
Low